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Increased nitric oxide inactivation by reactive oxygen species peroxidation product malondialdehyde (MDA) in ani-
in lead-induced hypertension. mals with experimental lead-induced HTN [8]. This find-
Background. We have recently found evidence for increased ing pointed to enhanced lipid peroxidation by reactivereactive oxygen species (ROS) in rats with lead-induced hyper-
oxygen species (ROS) in the lead-treated animals. Wetension. We hypothesized that increased ROS activity may
hypothesized that increased ROS activity may contributecontribute to hypertension by enhancing inactivation of nitric
oxide (NO) in this model. to the genesis or maintenance of HTN by oxidation and
Methods. Rats were treated for 12 weeks with either lead inactivation of nitric oxide (NO), otherwise known as
acetate (100 p.p.m.) alone (Pb group) or lead acetate plus endothelium-derived relaxing factor (EDRF). In an at-vitamin E-fortified food (5000 U/kg rat chow, Pb 1 E group).
tempt to explore the possible role of excess ROS activityThe control animals were fed either regular rat chow or a
in the pathogenesis of lead-induced HTN, we treated avitamin E-fortified diet. Blood pressure, creatinine clearance,
and urinary excretion of stable NO metabolites (NOx) were subgroup of the animals with des-methyltirilazad, a po-
monitored, and plasma and tissue abundance of nitrotyrosine, tent antioxidant and lipid peroxidation inhibitor. The
which is the footprint of NO oxidation by ROS, were deter- administration of des-methyltirilazad for two weeks re-mined.
sulted in parallel reductions in the arterial blood pressureResults. The Pb group showed a marked rise in blood pres-
and plasma MDA concentration to normal levels withoutsure, a significant increase in plasma and kidney, heart, liver,
and brain nitrotyrosine abundance, and a substantial fall in affecting the blood lead concentration [8]. In a subse-
urinary NOx excretion. Concomitant administration of high- quent study, we demonstrated normalizations of plasma
dose vitamin E in the Pb 1 E group ameliorated hypertension MDA and arterial blood pressure with the ROS scaven-and normalized both urinary NOx excretion and tissue nitroty-
ger 2,3-dimercaptosuccinic acid (DMSA) in this modelrosine without altering tissue lead content. However, vitamin
[9]. Based on these observations, we concluded that ex-E supplementation had no discernible effect on either blood
pressure or nitrotyrosine abundance in the normal controls. cess ROS activity might play a major role in the patho-
Conclusions. These findings point to enhanced ROS-medi- genesis of lead-induced HTN [8, 9]. We speculated that
ated inactivation and sequestration of NO, which can poten- enhanced oxidation/inactivation of NO by ROS may, intially contribute to hypertension, tissue damage, and reduced
part, contribute to the associated HTN. However, theurinary NOx excretion in rats with lead-induced hypertension.
latter studies did not explore the direct evidence for NOThe beneficial effects of high-dose vitamin E on blood pressure,
tissue nitrotyrosine burden, and urinary NOx excretion support oxidation by ROS. This study was therefore designed to
the role of increased ROS activity in the pathogenesis of these test the hypothesis that lead-induced HTN is associated
abnormalities in this model. with enhanced NO oxidation by ROS. To this end, we
determined plasma and tissue nitrotyrosine, which is the
footprint of the NO–ROS interaction. NO avidly reacts
Extended exposure to low levels of lead can cause with superoxide (O•22 ) and other ROS to produce perox-systemic hypertension (HTN) in both humans and labo- ynitrite (ONOO2), a highly cytotoxic reactive nitrogen
ratory animals [1–7]. In a recent study, we found a sig- species. Peroxynitrite, in turn, avidly reacts with and
nificant increase in the plasma concentration of lipid damages proteins, lipids, and DNA [10]. For instance,
peroxynitrite reacts with tyrosine residues of proteins
to produce nitrotyrosine, which can be detected in theKey words: lead, oxidative stress, vitamin E, tocopherol, antioxidant,
hypertension. plasma and various tissues. Alternatively, ROS can ini-
tially react with tyrosine to produce tyrosyl radicals thatReceived for publication November 25, 1998
can, in turn, oxidize NO and generate nitrotyrosine [11].and in revised form April 14, 1999
Accepted for publication May 18, 1999 In addition, nitrotyrosine can be formed from an interac-
tion of nitrogen dioxide with tyrosine residues of proteins 1999 by the International Society of Nephrology
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[11, 12]. Consequently, nitrotyrosine abundance is gener- were centrifuged at 12,000 g for five minutes at 48C,
and the supernatant was used for the determination ofally considered as an indicator of NO oxidation by ROS.
nitrotyrosine abundance. The protein concentration was
determined by using a BCA protein assay kit (Pierce
METHODS
Inc., Rockford, IL, USA).
Animals
Measurement of nitrotyrosineMale Sprague Dawley rats (Harlan Sprague Dawley
Inc., Indianapolis, IN, USA) with an average weight of Plasma and tissue nitrotyrosine abundance was deter-
mined by Western blot as previously described [15] using200 g were used. They were fed regular rat chow (con-
taining tocopherol 40 U/kg) and water ad libitum. The an antinitrotyrosine monoclonal antibody (Upstate Bio-
technology Inc., Lake Placid, NY, USA). Briefly, plasmaanimals were randomized into lead-treated and control
groups. The drinking water in the lead-treated group and tissue preparations (100 mg of protein) were size-
fractionated on 4 to 20% Tris-Glycine gel (Novex Inc.,was supplemented with lead acetate (100 p.p.m.) for 12
weeks. In contrast, the control groups were provided San Diego, CA, USA) at 120 V for two hours. In prelimi-
nary experiments, we had found that the given proteinwith distilled water throughout the observation period.
In an attempt to discern the role of increased ROS, concentrations were within the linear range of detection
for our Western blot technique. After electrophoresis,additional groups of six lead-treated and six normal con-
trol rats were fed a vitamin E-fortified diet to reduce proteins were transferred onto polyvinylidine difluoride
(PVDF) membrane (Amersham Life Science Inc., Ar-ROS activity. The diet consisted of regular rat chow
containing 5000 U/kg tocopherol (prepared by Harlan lington Heights, IL, USA) at 200 mA for 120 minutes
using the Novex transfer system. The membrane wasTeklad, Inc., Madison, WI, USA). The arterial blood
pressure was determined using a tail sphygmomanome- prehybridized in buffer A (10 mm Tris hydrochloride,
pH 7.5, 100 mm NaCl, 0.1% Tween 20 and 5% nonfatter (Harvard Apparatus, Natick, MA, USA) as pre-
viously described [13]. The food intake was determined milk powder) for one hour and then hybridized overnight
at 48C in the same buffer containing 0.5 mg/ml antinitro-by subtracting the amount of food remaining after 24
hours from the predetermined excess food supplied to tyrosine monoclonal antibody. The membrane was then
washed for 30 minutes in a shaking bath while changingthe animals. Monitoring of the data for one week re-
vealed no significant difference in food consumption be- the wash buffer (buffer A without nonfat milk) every
five minutes. The membranes were subsequently incu-tween the study groups (33 6 2 in the controls vs. 35 6
3 g/day in the lead-treated group, P 5 NS). At week 12, bated for one hour in buffer A plus horseradish peroxi-
dase-conjugated goat antimouse IgG antibody at the finalthe animals were placed in metabolic cages for a 24-hour
urine collection. Under general anesthesia with Nembu- titer of 1:2000. Experiments were carried out at room
temperature. The washing procedure was repeated be-tal (50 mg/kg intraperitoneally) the animals were killed
by exsanguination using cardiac puncture. Plasma was fore the membrane was developed with a light emitting
nonradioactive method using ECL reagent (Amershamseparated; kidney, liver, heart, and brain were harvested,
cleaned in phosphate-buffered saline (PBS), frozen in Inc.). The membranes were then subjected to autolumi-
nography for 20 seconds to 5 minutes. The autolumino-liquid nitrogen, and stored at 2708C until processed.
Plasma and urinary creatinine concentration were graphs were scanned with a laser densitometer (Model
PD1211; Molecular Dynamics Inc., Sunnyvale, CA,measured using standard laboratory methods.
USA) to determine the relative optical densities of the
Total nitrate and nitrite assay bands. In all instances, the membranes were stained with
Ponceau stain to verify the uniformity of protein loadUrinary excretion of the total nitrite and nitrate (NOx)
was determined as previously described [14] using the and transfer efficiency.
purge system of a Sievers Instruments Model 270B Nitric
Tissue lead determinationOxide Analyzer (NOAe; Sievers Instruments Inc., Boul-
der, CO, USA). Slices of renal cortex were dried at 708C for 24 hours.
The samples were then weighed and processed for lead
Tissue preparation measurement using an atomic absorption spectrometer
(Model 305 with graphite furnace; Perkin-Elmer, Nor-Brain, heart, liver, and kidney were processed for de-
termination of nitrotyrosine. The tissues (25% wt/vol) walk, CT, USA). Kidney tissue lead contents were ex-
pressed as microgram per gram of dry tissues.were homogenized in a solution containing 50 mm Tris-
HCl (pH 7.4); 1% NP-40; 0.25% sodium deoxycholate;
Data analysis150 mm NaCl; 1 mm EGTA; aprotinin, leupeptin, pep-
statin (1 mg/ml each); 1 mm Na3VO4; and 1 mm NaF at Analysis of variance, Student’s t-test, and regression
analysis were used in statistical analysis of the data, which0 to 48C using a polytron homogenizer. Homogenates
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Fig. 1. Longitudinal measurements of arterial blood pressure in the Fig. 2. Upper panel depicts representative Western blot of nitrotyro-
normal control (d) group and rats treated with lead alone (j) or lead sine in the plasma of two normal control rats (NL), two rats treated
plus vitamin E supplement (m) during a 12-week treatment period. with lead alone (Pb), and two rats treated with lead plus vitamin E
N 5 6 in each group; *P , 0.01 vs. control group; 1P , 0.05 vs. Pb (Pb 1 E) for a 12-week period. The corresponding group data are
group. illustrated in the lower panel. N 5 6 in each group; *P , 0.01 vs. other
groups, analysis of variance.
Table 1. Body weight, creatinine clearance (CCr) and urinary
excretions of protein and stable nitric oxide metabolites (NOx) in
the untreated normal control group (CTL) and rats treated with
lead alone (Pb group) or lead plus vitamin E supplement
(Pb1E group)
CTL Pb Pb1E
Body weight g 425614 425614 42268
CCr ml/min 2.0160.35 2.3760.22 2.1260.51
Urinary Nox excretion
lm /5 hours 1.6260.32 0.6360.16a 1.2060.25
Urinary protein
mg/24 hr 16.1962.45 21.8463.62 17.0664.63
N 6 6 6
a P , 0.01 (ANOVA)
are presented as mean 6 sem. P values , 0.05 were
considered significant.
Fig. 3. Longitudinal measurements of plasma nitrotyrosine abundance
RESULTS in the normal control (d) group and rats treated with lead alone (j)
or lead plus vitamin E supplement (m) during a 12-week treatmentEffect of lead period. N 5 6 at each time point in each group; *P , 0.01 vs. the other
groups, analysis of variance.As expected, the lead-treated group exhibited a sig-
nificant rise in the arterial blood pressure as compared
with the normal control group (Fig. 1). In contrast, uri-
nary excretion of stable NO metabolites, that is, total
nitrate and nitrite, was significantly reduced in the lead- group showed a marked increase in nitrotyrosine abun-
dance in the plasma (P , 0.01). Likewise, nitrotyrosinetreated group. This observation is consistent with our
previous findings in this model [8, 9]. No significant dif- expression was significantly increased in the brain (P ,
0.02), heart (P , 0.01), liver (P , 0.01), and kidney (P ,ferences were found in body weight, hematocrit, or creat-
inine clearance between the lead-treated and the control 0.03) of the lead-treated group as compared with the
corresponding values found in the control group (Figs.groups (Table 1).
Compared with the control group, the lead-treated 2–7). There was a direct correlation between blood pres-
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Fig. 4. Upper panel depicts representative Western blot of nitrotyro- Fig. 6. Upper panel depicts representative Western blot of nitrotyro-
sine in the brain of two normal control rats (NL) and two rats each sine in the kidney of two normal control rats (NL) and two rats each
treated with lead alone (Pb) or lead plus vitamin E (Pb 1 E) for a 12- treated with lead alone (Pb) or lead plus vitamin E (Pb 1 E) for a 12-
week period. The corresponding group data are illustrated in the lower week period. The corresponding group data are illustrated in the lower
panel. N 5 6 in each group; *P , 0.02 vs. other groups, analysis of panel. N 5 6 in each group; *P , 0.03 vs. other groups, analysis of
variance. variance.
Fig. 5. Upper panel depicts representative Western blot of nitrotyro- Fig. 7. Upper panel depicts representative Western blot of nitrotyro-
sine in the liver of two normal control rats (NL) and two rats each sine in the heart of two normal control rats (NL) and two rats each
treated with lead alone (Pb) or lead plus vitamin E (Pb 1 E) for a 12- treated with lead alone (Pb) or lead plus vitamin E (Pb 1 E) for a 12-
week period. The corresponding group data are illustrated in the lower week period. The corresponding group data are illustrated in the lower
panel. N 5 6 in each group; *P , 0.01 vs. other groups, analysis of panel. N 5 6 in each group; *P , 0.01 vs. other groups, analysis of
variance. variance.
blood pressure (r 5 20.79, P , 0.05) and nitrotyrosinesure and nitrotyrosine abundance in the plasma (r 5
0.79, P , 0.05), liver (r 5 0.93, P , 0.01), brain (r 5 abundance in the plasma (r 5 20.79, P , 0.05), liver
(r 5 20.77, P , 0.05), brain (r 5 20.70), P , 0.05),0.73, P , 0.05), heart (r 5 0.84, P , 0.01), and kidney
(r 5 0.75, P , 0.05). In contrast, urinary excretion of heart (r 5 20.82, P , 0.01), and kidney (r 5 20.71, P ,
0.05).total nitrate and nitrite was inversely related to arterial
Vaziri et al: NO inactivation in lead-induced HTN1496
Effect of vitamin E
Arterial blood pressure in the lead-treated animals
consuming a vitamin E-fortified diet was significantly
(P , 0.05) lower than that found in the lead-treated
group given a regular diet (Fig. 1). However, vitamin
E supplementation had no effect on renal tissue lead
concentration (8.3 6 0.9 and 10.8 6 1.0 mg/g dry weight in
the lead-treated and lead plus vitamin E-treated groups,
respectively). Vitamin E therapy prevented the rise in
plasma, kidney, brain, heart, and liver nitrotyrosine ex-
pression and abrogated the decline in urinary NOx excre-
tion in the lead-treated animals (Figs. 2–7 and Table 1).
In contrast to the effects seen in the lead-treated animals,
vitamin E supplementation had no effect on either blood
pressure (120 6 4 in untreated controls and 119 6 3 mm
Hg in vitamin E-treated controls) or tissue nitrotyrosine
abundance in normal animals (Figs. 8 and 9). Likewise,
vitamin E supplementation did not affect urinary NO
metabolite excretion (588 6 53 in the untreated controls
vs. 578 6 52 mm/g creatinine in the vitamin E-treated
controls).
DISCUSSION
In contrast to the exposure to high levels of lead, which
causes nephropathy, exposure to low levels of lead, as
employed here, has been shown to cause HTN with mini-
Fig. 8. Representative Western blots of nitrotyrosine in brain, heart,
mal histological and ultrastructural changes and no func- kidney, liver and plasma of two untreated normal control (NL) rats
and two vitamin E-treated normal control (NL 1 E) rats.tional impairment of the kidney [16]. The lead-treated
animals used in this study showed a significant rise in
arterial blood pressure and a significant fall in urinary
excretion of NO metabolites, that is, total nitrate and
creased ROS activity in the pathogenesis of depressednitrite. These observations confirm the results of our
urinary NOx excretion and increased tissue nitrotyrosineearlier studies in this model [8, 9]. It should be noted
accumulation is supported by their prevention by antiox-that body weight and food intake, and hence, the dietary
idant therapy with vitamin E supplementation as shownconsumptions of l-arginine and nitrate/nitrite, were simi-
in this study.lar in the lead-treated and the control groups. Thus, the
It is of interest that antioxidant therapy with vitaminreduction in urinary NOx in the lead-treated rats was
E supplementation had no effect on either blood pres-unrelated to either dietary nitrate/nitrite or l-arginine
sure or tissue nitrotyrosine abundance in normal rats,contents. Instead, it was most likely due to either de-
contrasting with the results found in the lead-treatedpressed total body NO production and/or NO sequestra-
group. This observation suggests that under normal cir-tion. In a recent study, we have demonstrated a marked
cumstances, the natural antioxidant defense system isup-regulation of renal and vascular tissue NOS isotype
sufficient to contain the endogenous ROS generated inexpression in rats with lead-induced HTN, suggesting
the intact animals. Thus, in the absence of oxidativeenhanced NO production capacity in this model [17].
stress, additional antioxidant supplies have minimal im-Increased nitrotyrosine abundance in the tested tissues
pact on this process. In contrast, in the presence of oxida-found in this study provides tangible evidence for sub-
tive stress that is defined by the imbalance between ROSstantial sequestration of NO in various tissues of animals
generation and natural antioxidant capacity, exogenouswith lead-induced HTN. This phenomenon can, in part,
antioxidant can clearly help to restore oxidant-antioxi-account for the reduction in urinary excretion of NO
dant balance. The validity of this contention was clearlymetabolites. In addition, the generation of nitrotyrosine,
evident in the differential response to vitamin E supple-which involves ROS-mediated oxidation of NO, may
mentation observed in the normal and lead-exposed ani-necessarily limit NO availability to vascular smooth mus-
mals employed in this study.cle. This can, in turn, contribute to the rise in the systemic
vascular resistance and blood pressure. The role of in- The oxidation of NO by superoxide and other ROS
leads to generation of peroxynitrite, which is an ex-
tremely cytotoxic radical [10]. Peroxynitrite and its nox-
ious by-products deplete tissue antioxidant stores and
modify and functionally impair proteins, lipids, and
DNA [18–27]. In fact, the increased production of the
peroxynitrite as judged by accumulation of nitrotyrosine
has been implicated in the pathogenesis of tissue damage
in many degenerative, ischemic, and inflammatory condi-
tions such as neurodegenerative disorders, atherosclero-
sis, senescence, rheumatoid arthritis, AIDS, inflamma-
tory bowel disease, and septic shock [10]. The presence of
increased abundance of plasma and tissue nitrotyrosine,
which is a marker of NO oxidation by ROS, supports our
original hypothesis that lead-induced HTN is associated
with enhanced NO oxidation by ROS.
An increase in ROS activity and abnormal nitration of
proteins in various tissues in animals with lead-induced
HTN may, in part, account for development of HTN
and renal and vascular complications in patients with
chronic exposure to low levels of lead. If true, the use
of antioxidants may be a useful adjunct in the treatment
of such patients. Further studies are needed to explore
this possibility. In fact, high-dose vitamin E supplemen-
tation resulted in a marked attenuation of lead-induced
HTN in our vitamin E-treated rats. This was associated
with a significant reduction in plasma and tissue nitroty-
rosine abundance and a substantial rise in urinary NOx
excretion. These observations suggest that by diminish-
ing the ROS activity, vitamin E mitigated the ROS-asso-
ciated inactivation and sequestration of NO in the lead-
treated animals. This, in turn, enhanced NO availability
to vascular smooth muscle leading to the amelioration of
HTN. The favorable antihypertensive response to high-
dose vitamin E in animals with lead-induced HTN is
consistent with a similar response to other ROS scaven-
gers, dimercaptosuccinic acid, des-methyltirilazad and
dimethylthiourea in this model previously shown by our
group [4, 6, 8, 9].
In conclusion, animals with lead-induced HTN exhib-
ited a marked reduction in urinary NOx excretion and
a significant increase in tissue and plasma nitrotyrosine
abundance. High-dose vitamin E administration amelio-
rated HTN, reduced tissue nitrotyrosine abundance, and
increased urinary NOx excretion. These observations
point to enhanced NO oxidation by ROS in animals with
lead-induced HTN. Active consumption of NO by ROS
can contribute to HTN by limiting NO availability. In
addition, peroxidation of lipids shown earlier [8, 9] and
nitrosylation of proteins shown here can contribute to
b
Fig. 9. Group data illustrating (A) brain, (B) heart, (C) kidney, (D)
liver, and (E) plasma nitrotyrosine abundance in six untreated normal
control (NL) rats and six vitamin E-treated control (NL 1 E) rats. No
significant difference was found in tissue nitrotyrosine abundance in
any of the tested tissues between the two groups.
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